A PHASE 1B DOSE ESCALATION STUDY OF THE COMBINATION OF THE BISPECIFIC T CELL REDIRECTION ANTIBODIES TALQUETAMAB AND TECLISTAMAB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
2019-004124-38CANCER DE MEDULA OSEAFundación Jiménez DíazInvestigador: ASKARI ASKARI ELHAM